Publicaciones en colaboración con investigadores/as de Universidade de Lisboa (24)

2024

  1. Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank

    Clinical and experimental rheumatology, Vol. 42, Núm. 2, pp. 277-287

2022

  1. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

    Annals of the rheumatic diseases, Vol. 81, Núm. 7, pp. 970-978

  2. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

    The Lancet Rheumatology, Vol. 4, Núm. 9, pp. e603-e613

  3. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

    Arthritis Care and Research, Vol. 74, Núm. 7, pp. 1205-1218

  4. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis

    Rheumatology (Oxford, England), Vol. 61, Núm. 12, pp. 4741-4751

2021

  1. Association between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death among Patients with Immune-Mediated Inflammatory Disease and COVID-19

    JAMA Network Open

  2. Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts

    Frontiers in Immunology, Vol. 12

2020

  1. Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis

    Rheumatology (United Kingdom), Vol. 59, Núm. 9, pp. 2455-2461

  2. NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients

    Pharmacogenomics Journal, Vol. 19, Núm. 1, pp. 83-96

  2. Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium

    Scientific Reports, Vol. 9, Núm. 1

  3. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 11, pp. 1536-1544

2017

  1. 2016 update of the EULAR recommendations for the management of early arthritis

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 6, pp. 948-959

  2. Rituximab retreatment in rheumatoid arthritis in a real-life cohort: Data from the CERERRA collaboration

    Journal of Rheumatology, Vol. 44, Núm. 2, pp. 162-169

2016

  1. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration

    Arthritis Research and Therapy, Vol. 18, Núm. 1

  2. Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration [Arthritis Res Ther. 18: (2016); 50], doi: 10.1186/s13075-016-0951-z

    Arthritis Research and Therapy

2015

  1. Genetic variants within immune-modulating genes influence the risk of developing rheumatoid arthritis and anti-TNF drug response: A two-stage case-control study

    Pharmacogenetics and Genomics, Vol. 25, Núm. 9, pp. 432-443

  2. Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: A multicenter study

    Pharmacogenetics and Genomics, Vol. 25, Núm. 7, pp. 323-333

  3. The EULAR Study Group for Registers and Observational Drug Studies: Comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers

    Rheumatology (United Kingdom), Vol. 54, Núm. 6, pp. 1074-1079

2014

  1. The International Criteria for Behçet's Disease (ICBD): A collaborative study of 27 countries on the sensitivity and specificity of the new criteria

    Journal of the European Academy of Dermatology and Venereology, Vol. 28, Núm. 3, pp. 338-347